Which Has More Side Effects: Wegovy or Zepbound?

Last reviewed: July 9, 2026

Last updated: July 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy (semaglutide) and Zepbound (tirzepatide) are both prescription medications for weight loss, but they work through different biological pathways. Wegovy targets the GLP-1 receptor alone, while Zepbound activates both GLP-1 and GIP receptors simultaneously. Because of this fundamental difference in how they function, patients often experience varying side effect severity and frequency between the two medications.

How Wegovy and Zepbound Side Effects Differ by Mechanism

Wegovy stimulates only the glucagon-like peptide-1 receptor, which slows gastric emptying and increases feelings of fullness. This single-target approach tends to produce gastrointestinal side effects in about 40–50% of users during dose escalation. Common reactions include nausea, vomiting, and constipation, which typically peak during the first 2–4 weeks and gradually decrease as the body adapts.

Zepbound activates two receptors—GLP-1 and the glucose-dependent insulinotropic polypeptide (GIP) receptor—simultaneously. This dual action enhances weight loss but may increase the frequency of nausea and appetite suppression in some patients. Clinical trials showed that gastrointestinal events occurred in approximately 45–48% of Zepbound users, comparable to Wegovy but with potentially different severity patterns depending on individual receptor sensitivity.

The key distinction lies in how quickly side effects emerge and resolve. Wegovy users often report a gradual onset and offset, while Zepbound's dual-pathway activation can produce more pronounced initial nausea. However, long-term tolerability between the two medications is similar for most patients after 8–12 weeks of consistent dosing.

Most Common Side Effects: Nausea, Vomiting, and Constipation

Both Wegovy and Zepbound carry the same primary safety concerns: nausea ranks as the most frequently reported adverse event, affecting 25–40% of users depending on dose level. Vomiting occurs less frequently (5–10%) but can be severe enough to prompt dose reduction or temporary treatment pause. Constipation affects 15–25% of patients and often persists longer than nausea, requiring proactive dietary fiber intake and hydration strategies.

Rare but serious side effects include pancreatitis, severe allergic reactions, and thyroid tumors in animal models (though not yet confirmed in humans). All patients receive black-box warning information about the potential risk of thyroid C-cell tumors based on rodent studies; however, human epidemiological data remains limited. Both medications carry contraindication in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.

Genetic Factors Influencing Your Side Effect Risk

Individual responses to Wegovy and Zepbound are partially determined by genetic variation in GLP1R and GIPR genes. The GLP1R rs6923761 variant affects how efficiently your cells respond to semaglutide, while GIPR rs1800437 impacts your sensitivity to tirzepatide's dual action. Patients with certain genetic profiles may experience stronger nausea or faster symptom resolution based on their peptide-pathway genetics.

PlexusDx Precision Peptide Genetic Test maps 14 metabolic pathways and 49 peptides to identify your genotype-specific predisposition to GLP-1 and GIP receptor sensitivity. This test reveals whether you carry variants that increase gastrointestinal side effect risk or enhance medication efficacy. Understanding your genetic blueprint allows providers to select the medication most likely to produce meaningful weight loss with tolerable side effects tailored to your biology.

Choosing Between Wegovy, Zepbound, and Compounded Alternatives

PlexusDx offers compounded semaglutide injections starting at $149 per month and compounded tirzepatide injections beginning at $249 per month, both from licensed 503A pharmacies. Compounded versions provide the same active pharmaceutical ingredients as brand-name products but at a fraction of the cost and without insurance requirements. Your dose may need to go up during treatment titration—a standard and expected part of therapy—but your price remains flat throughout your commitment tier.

For patients uncertain whether single or dual-pathway activation suits them best, PlexusDx also offers GLP-Squared Injection, which combines both semaglutide and tirzepatide in one formulation starting at $249 per month. This hybrid approach allows simultaneous exposure to both receptor pathways, potentially reducing side effect intensity while maximizing metabolic benefit. All PlexusDx medications are HSA and FSA eligible and available in all 50 states without membership fees or insurance prerequisites.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Does Zepbound cause more nausea than Wegovy?

Clinical trial data shows comparable nausea rates between the two medications (25–40%), but individual experiences vary. Zepbound's dual GLP-1/GIP activation may trigger more intense initial nausea in some patients, while Wegovy's single-target approach tends to produce gradual onset. Your genetic profile determines whether you'll tolerate one medication better than the other.

Can I reduce side effects by choosing a different medication?

Yes. Switching from Wegovy to Zepbound (or vice versa) can improve tolerability if you experience intolerable nausea or constipation. Your genetic variants in GLP1R and GIPR influence how strongly you respond to each pathway, making some patients better suited to one medication. PlexusDx genetic testing identifies your personalized pathway sensitivity to guide this decision.

How much does PlexusDx compounded tirzepatide cost compared to Zepbound?

PlexusDx compounded tirzepatide injections start at $249 per month and remain flat regardless of your dose level—your dose may need to go up, but your price won't. Brand-name Zepbound typically costs $1,000+ monthly without insurance. PlexusDx tirzepatide is HSA and FSA eligible and available in all 50 states without membership fees or insurance requirements.

Which medication is safer: Wegovy or Zepbound?

Both medications carry similar safety profiles and FDA approval for chronic weight management. The primary concerns are gastrointestinal side effects during dose escalation and theoretical thyroid risk based on animal studies. Neither medication is inherently safer; safety depends on individual tolerability, medical history, and genetic factors that influence your response to receptor activation.

Can the Precision Peptide Genetic Test predict my side effect risk?

Yes. PlexusDx Precision Peptide Genetic Test analyzes genetic variants in GLP1R rs6923761 and GIPR rs1800437 (among others) that directly influence your sensitivity to GLP-1 and GIP receptor activation. Patients with specific genotypes experience higher gastrointestinal side effect risk or faster symptom resolution. The test costs $99 as an add-on after your first month of treatment and maps 150+ genetic insights across 14 metabolic pathways.

Related Reading

• Zepbound Side Effects
• Wegovy Side Effects
• Wegovy Vs Zepbound 2
• Zepbound Vs Wegovy 2

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.